ID: ALA411789

Max Phase: Preclinical

Molecular Formula: C63H113N11O14

Molecular Weight: 1248.66

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CC[C@H]1NC(=O)[C@H]([C@H](O)[C@H](C)CCCC(=O)OC)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O

Standard InChI:  InChI=1S/C63H113N11O14/c1-25-43-59(83)68(17)33-48(75)69(18)44(29-34(2)3)56(80)67-50(38(10)11)62(86)70(19)45(30-35(4)5)55(79)64-41(15)54(78)65-42(16)58(82)71(20)46(31-36(6)7)60(84)72(21)47(32-37(8)9)61(85)73(22)51(39(12)13)63(87)74(23)52(57(81)66-43)53(77)40(14)27-26-28-49(76)88-24/h34-47,50-53,77H,25-33H2,1-24H3,(H,64,79)(H,65,78)(H,66,81)(H,67,80)/t40-,41-,42+,43-,44+,45-,46+,47+,50+,51-,52+,53-/m1/s1

Standard InChI Key:  SHCGDZWYXUVNNK-LHCCYJQJSA-N

Associated Targets(Human)

Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform 1831 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1248.66Molecular Weight (Monoisotopic): 1247.8468AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Lazarova T, Chen JS, Hamann B, Kang JM, Homuth-Trombino D, Han F, Hoffmann E, McClure C, Eckstein J, Or YS..  (2003)  Synthesis and biological evaluation of novel cyclosporin a analogues: potential soft drugs for the treatment of autoimmune diseases.,  46  (5): [PMID:12593646] [10.1021/jm025595i]

Source